Pharmacogenomic Impact on Breast Cancer Survival for Black Zimbabwean Patients on Tamoxifen
Individuals with hormone receptor-positive breast cancer who are CYP2D6 NM had better disease recurrence and progression-free survival outcomes compared with IM.
Authors
- Tinashe Mazhindu (ORCID: https://orcid.org/0000-0003-3446-3049)
- Margaret Borok (ORCID: https://orcid.org/0000-0002-1234-0913)
- Audrey E. Hendricks (ORCID: https://orcid.org/0000-0002-7152-0287)
- Ntokozo Ndlovu (ORCID: https://orcid.org/0000-0002-8269-7571)
- Collen Masimirembwa (ORCID: https://orcid.org/0000-0002-4053-212X)
- M. Robinson Joel (ORCID: https://orcid.org/0009-0007-6038-2345)
- Elisabeth Chase (ORCID: https://orcid.org/0000-0003-2698-7360)
Institutions
- University of Zimbabwe (ZW)
- African Institute of Biomedical Science and Technology (ZW)
- University of Colorado Anschutz Medical Campus (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- JCO Global Oncology
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1200/go-25-00367
- Citations
- 1
- Primary Topic
- Pharmacogenetics and Drug Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 1.56